Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine - Concepedia

Concepedia

Publication | Open Access

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

DOI Full Paper Access

156

Citations

9

References

2021

Year

Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, Christian Récher, Andre C. Schuh, Michael J. Thirman, Jacqueline S. Garcia, Courtney D. DiNardo, Vladimir Vorobyev, Nicola Fracchiolla,

Journal of Clinical Oncology

Abstract

Patients who achieved CRc and MRD < 10<sup>-3</sup> with venetoclax and azacitidine had longer DoR, EFS, and OS, than responding patients with MRD ≥ 10<sup>-3</sup>.

References

	Year	Citations

Page 1